HCPCS drug code · CMS crosswalk
Avtozma HCPCS Code
In short
Avtozma is billed under HCPCS Q5156 — Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg. One billing unit is 1 mg. CMS's crosswalk lists 3 Avtozma NDCs under this code.
Reference
- Q5156
- Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mgBilling unit: 1 mg
- Labelers
- Celltrion USA, Inc.
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. CMS note: 8% of reference add-on applied. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Avtozma units and claim line
Enter the dose given to get the Q5156 units and the NDC line for the CMS-1500 and the 837P.
Enter the dose given to build the claim line.
Avtozma NDCs and billing units
From CMS’s ASP NDC–HCPCS crosswalk, effective October 1, 2026 through December 31, 2026. Billing units per package are CMS’s figures for the code’s unit.
| NDC (11-digit) | HCPCS | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| 72606-0042-01 | Q5156 | Celltrion USA, Inc. | 4 | 80 |
| 72606-0043-01 | Q5156 | Celltrion USA, Inc. | 10 | 200 |
| 72606-0044-01 | Q5156 | Celltrion USA, Inc. | 20 | 400 |
Avtozma: common questions
- What is the HCPCS code for Avtozma?
- Avtozma is billed under HCPCS Q5156 — Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg. One billing unit is 1 mg. CMS's crosswalk lists 3 Avtozma NDCs under this code.
- How many Q5156 billing units are in a package of Avtozma?
- CMS lists 80 to 400 billing units per package, depending on the NDC, where one unit is 1 mg. Units to report are based on the dose given, not the package.
- Is Q5156 a CPT code?
- No. Q5156 is a HCPCS Level II code from CMS for the drug itself. Giving it, for example by injection or infusion, is usually reported with a separate CPT administration code.
Other codes for the same drug
- J3262Injection, tocilizumab, 1 mg
- Q0234Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg
- Q0237Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
- Q0238Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
- Q0249Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
- Q5133Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg
- Q5135Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg